Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05467709 · ClinicalTrials.gov registry record · Phase 1
Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects
A Phase 1 study of Health Volunteers, sponsored by Concert Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05467709 is a Phase 1 study of Health Volunteers that has completed, run by Concert Pharmaceuticals. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05467709, a Phase 1 study of Health Volunteers, has completed, sponsored by Concert Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center, Phase 1, open-label, fixed-sequence, drug-drug interaction study to determine the effect of CTP-543 on the pharmacokinetics (PK) of midazolam in healthy adult subjects
Conditions Studied
Interventions
- DRUG Midazolam
- DRUG CTP-543
Study Locations (1)
Florida
- Clinical Pharmacology of Miami, LLC - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-06-21 |
| Est. Completion | 2022-07-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05467709
The ClinicalTrials.gov registry entry for NCT05467709 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Concert Pharmaceuticals, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Health Volunteers appearing as the primary indexed condition, and to 2 interventions - of which Midazolam is the first listed.
NCT05467709 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05467709 about?
NCT05467709 is a clinical study titled "Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects". This is a single center, Phase 1, open-label, fixed-sequence, drug-drug interaction study to determine the effect of CTP-543 on the pharmacokinetics (PK) of midazolam in healthy adult subjects
What is the current status of trial NCT05467709?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2022-06-21. Estimated completion is 2022-07-07.
What conditions does trial NCT05467709 study?
This clinical trial studies the following conditions: Health Volunteers.
What interventions are being tested in trial NCT05467709?
The interventions under investigation include: Midazolam (DRUG), CTP-543 (DRUG).
Who is sponsoring clinical trial NCT05467709?
This trial is sponsored by Concert Pharmaceuticals, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05467709 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Health Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.